|66.80||+0.3000||+0.45%||Vol 830.13K||1Y Perf -13.77%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||106.73||Analyst Rating||Strong Buy 1.36|
|Potential %||59.78||Finscreener Ranking||★★★ 48.64|
|Insiders Trans % 3/6/12 mo.||-50/-50/-97||Value Ranking||★+ 44.65|
|Insiders Value % 3/6/12 mo.||-92/-92/-100||Growth Ranking||★★★★★ 70.12|
|Insiders Shares Cnt. % 3/6/12 mo.||-91/-91/-100||Income Ranking||★+ 37.16|
|Price Range Ratio 52W %||4.14||Earnings Rating||Sell|
|Market Cap||10.57B||Earnings Date||7th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||7th Nov 2023|
|Estimated EPS Next Report||0.40|
|EPS Growth Next 5 Years %||10.50|
|Avg. Weekly Volume||906.15K|
|Avg. Monthly Volume||858.53K|
|Avg. Quarterly Volume||795.61K|
Bio-Techne Corp (NASDAQ: TECH) stock closed at 66.5 per share at the end of the most recent trading day (a -0.97% change compared to the prior day closing price) with a volume of 1.04M shares and market capitalization of 10.57B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3000 people. Bio-Techne Corp CEO is Charles R. Kummeth.
The one-year performance of Bio-Techne Corp stock is -13.77%, while year-to-date (YTD) performance is -19.76%. TECH stock has a five-year performance of 40.24%. Its 52-week range is between 65.77 and 90.6325, which gives TECH stock a 52-week price range ratio of 4.14%
Bio-Techne Corp currently has a PE ratio of 46.20, a price-to-book (PB) ratio of 7.40, a price-to-sale (PS) ratio of 15.53, a price to cashflow ratio of 40.50, a PEG ratio of 4.40, a ROA of 13.66%, a ROC of 14.64% and a ROE of 18.59%. The company’s profit margin is 25.22%, its EBITDA margin is 40.50%, and its revenue ttm is $848.26 Million , which makes it $5.40 revenue per share.
Of the last four earnings reports from Bio-Techne Corp, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.40 for the next earnings report. Bio-Techne Corp’s next earnings report date is 07th Nov 2023.
The consensus rating of Wall Street analysts for Bio-Techne Corp is Strong Buy (1.36), with a target price of $106.73, which is +59.78% compared to the current price. The earnings rating for Bio-Techne Corp stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bio-Techne Corp has a dividend yield of 0.38% with a dividend per share of $0.32 and a payout ratio of 27.00%.
Bio-Techne Corp has a Sell technical analysis rating based on Technical Indicators (ADX : 12.04, ATR14 : 1.79, CCI20 : -122.72, Chaikin Money Flow : -0.22, MACD : -2.92, Money Flow Index : 38.96, ROC : -9.71, RSI : 24.34, STOCH (14,3) : 6.77, STOCH RSI : 0.00, UO : 36.99, Williams %R : -93.23), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bio-Techne Corp in the last 12-months were: Charles Kummeth (Option Excercise at a value of $10 856 251), Charles Kummeth (Sold 322 shares of value $26 726 ), Charles R. Kummeth (Option Excercise at a value of $10 856 251), Kelderman Kim (Sold 0 shares of value $-99 960 ), Nusse Roeland (Option Excercise at a value of $349 600), Nusse Roeland (Sold 8 939 shares of value $717 981 )
Mon, 11 Sep 2023 13:01 GMT Analysts Conflicted on These Technology Names: Bio-Techne (TECH) and Upstart Holdings (UPST)- TipRanks. All rights reserved.
Wed, 30 Aug 2023 01:45 GMT Bio-Techne (TECH) Receives a Hold from RBC Capital- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.